Sugar-coated killer: serotype 3 pneumococcal disease

JN Luck, H Tettelin, CJ Orihuela - Frontiers in Cellular and Infection …, 2020 - frontiersin.org
Capsular polysaccharide (CPS), which surrounds the bacteria, is one of the most significant
and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents …

New insights into the mycobacterial PE and PPE proteins provide a framework for future research

LS Ates - Molecular microbiology, 2020 - Wiley Online Library
The PE and PPE proteins of Mycobacterium tuberculosis have been studied with great
interest since their discovery. Named after the conserved proline (P) and glutamic acid (E) …

Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era

S de Miguel, M Domenech… - Clinical Infectious …, 2021 - academic.oup.com
Background Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the
disease caused by vaccine serotypes in children, providing herd protection to adults …

The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi

U Obolski, TD Swarthout, A Kalizang'oma… - Nature …, 2023 - nature.com
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old
worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing …

Rapid inference of antibiotic resistance and susceptibility by genomic neighbour typing

K Břinda, A Callendrello, KC Ma, DR MacFadden… - Nature …, 2020 - nature.com
Surveillance of drug-resistant bacteria is essential for healthcare providers to deliver
effective empirical antibiotic therapy. However, traditional molecular epidemiology does not …

Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of …

HL Sings, P De Wals, BD Gessner… - Clinical Infectious …, 2019 - academic.oup.com
The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with
serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies …

Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate …

R Kaur, N Fuji, ME Pichichero - European Journal of Clinical Microbiology …, 2022 - Springer
The otopathogens colonizing the nasopharynx (NP) and causing acute otitis media (AOM)
have shown dynamic changes following introduction of pneumococcal conjugate vaccines …

Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018

DW Cleary, J Jones, RA Gladstone, KL Osman… - Scientific Reports, 2022 - nature.com
Streptococcus pneumoniae continues to cause significant disease burden. Whilst
pneumococcal conjugate vaccines (PCV) have substantially reduced this burden, serotype …

Factors affecting antimicrobial resistance in Streptococcus pneumoniae following vaccination introduction

ER Watkins, A Kalizang'Oma, A Gori, S Gupta… - Trends in …, 2022 - cell.com
Streptococcus pneumoniae is a major cause of pneumonia, meningitis, and septicaemia
worldwide. Pneumococcal antimicrobial resistance (AMR) has been highlighted by the WHO …

Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader

N Groves, CL Sheppard, D Litt, S Rose, A Silva… - Genes, 2019 - mdpi.com
Despite its inclusion in pneumococcal conjugate vaccine 13 (PCV13), Streptococcus
pneumoniae serotype 3 remains a major cause of invasive pneumococcal disease in …